Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

44.46USD
8:14pm IST
Change (% chg)

$-0.11 (-0.25%)
Prev Close
$44.57
Open
$44.33
Day's High
$44.48
Day's Low
$43.91
Volume
1,077,161
Avg. Vol
6,246,023
52-wk High
$45.81
52-wk Low
$33.20

Select another date:
Photo

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Oct 18 Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

Pfizer to cut around 2 percent of jobs through early next year

NEW YORK U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.

Pfizer to cut around 2 pct of jobs through early next year

NEW YORK, Oct 17 U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities.

FDA approves Pfizer's drug for advanced breast cancer

The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc's drug for an advanced form of breast cancer tied to an inherited gene mutation.

UPDATE 1-FDA approves Pfizer's drug for advanced breast cancer

Oct 16 The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 on Tuesday it approved Pfizer Inc's drug for an advanced form of breast cancer tied to an inherited gene mutation.

FDA approves Pfizer's breast cancer drug

Oct 16 The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 on Tuesday it approved Pfizer Inc's drug for advanced form of breast cancer.

Pfizer to replace longtime CEO Read with veteran Bourla

Pfizer Inc Chief Executive Officer Ian Read will hand over the reins of the largest U.S. drugmaker to veteran insider Albert Bourla in January, after eight years at the helm, in the backdrop of increased scrutiny over drug pricing.

UPDATE 6-Pfizer to replace longtime CEO Read with veteran Bourla

* Pfizer shares have risen 160 pct during Read's tenure (Adds background on Read and Bourla; updates shares)

Select another date: